natgillin/translations-raw huggingface dataset:
Erelzi in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. 
Zdravilo Erelzi je v kombinaciji z metotreksatom indicirano za zdravljenje zmernega do hudega aktivnega revmatoidnega artritisa pri odraslih, kadar odziv na zdravljenje z imunomodulirajočimi antirevmatičnimi zdravili, vključno z metotreksatom (če ta ni kontraindiciran), ni zadosten.
Patients were observed off treatment for the occurrence of rebound (PASI ≥ 150% of baseline) and for the time to relapse (defined as a loss of at least half of the improvement achieved between baseline and week 24). 
Bolnike so brez zdravljenja spremljali glede povratnih znakov (PASI ≥ 150 % izhodiščnega) in časa do recidiva (opredeljenega kot izginotje vsaj polovice izboljšanja, doseženega med izhodiščem in 24. tednom).
Stevens-Johnson syndrome, cutaneous vasculitis (including hypersensitivity vasculitis), erythema multiforme, lichenoid reactions 
Stevens-Johnsonov sindrom, kožni vaskulitis (vključno s preobčutljivostnim vaskulitisom), multiformni eritems, lihenoidne reakcije toksična epidermalna nekroliza
• Psoriatic arthritis in patients from the age of 12 years and weighing 62.5 kg or more. 
• psoriatičnega artritisa pri bolnikih, starejših od 12 let, ki tehtajo 62,5 kg ali več.
Erelzi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. 
Zdravilo Erelzi je mogoče uporabiti kot monoterapijo, kadar bolnik ne prenese metotreksata ali kadar trajno zdravljenje z metotreksatom ni primerno.
The safety and efficacy of etanercept were assessed in a two-part study in 69 children with polyarticular-course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset types (polyarthritis, pauciarthritis, systemic onset). 
Otroci z juvenilnim idiopatskim artritisom Varnost in učinkovitost etanercepta je bila ugotovljena v dvodelni študiji pri 69 otrocih s poliartikularnim potekom juvenilnega idiopatskega artritisa z različnimi tipi nastopa bolezni (poliartritis, oligoartritis, sistemski nastop).
• Request to ask the doctor to list other medications that may increase the risk of infection on the alert card 
• napotek bolniku, naj zdravnika prosi, da na opozorilno kartico za bolnika vpiše druga zdravila, ki bi lahko povečala tveganje za okužbo.
Tell your doctor if you or the child develop any change in the appearance of the skin or growths on the skin. 
če se pri vas ali otroku razvije kakšna sprememba videza kože ali rašče na koži.
Patients with a significant exposure to varicella virus should temporarily discontinue Erelzi therapy and be considered for prophylactic treatment with Varicella Zoster Immune Globulin. 
Bolniki, ki so zelo izpostavljeni virusu noric, naj začasno prekinejo zdravljenje z zdravilom Erelzi, v poštev pa pridejo tudi za profilaktično zdravljenje z imunoglobulinom proti virusu varicella-zoster.
Do not open the outer box until you are ready to use this medicine. 
Zunanjo škatlo odprite šele takrat, ko boste pripravljeni za injiciranje zdravila.
Your doctor may decide if you or the child need less anti-diabetic medicine while using Erelzi. 
Zdravnik lahko odloči, da boste vi ali otrok med uporabo zdravila Erelzi potrebovali manj zdravila za zdravljenje sladkorne bolezni.
Etanercept is a dimer of a chimeric protein genetically engineered by fusing the extracellular ligand binding domain of human tumour necrosis factor receptor-2 (TNFR2/p75) to the Fc domain of human IgG1. 
Etanercept je dimer himerne beljakovine, ustvarjen z genskim inženirstvom s spajanjem zunajcelične vezalne domene receptorja2 za humani tumorje nekrotizirajoči faktor (TNFR2/p75) in domene Fc humanega imunoglobulina IgG1.
• Dispose of the used pen in a sharps disposal container (i.e. a puncture-resistant closable container, or similar). 
• Uporabljen injekcijski peresnik odvrzite v zbiralnik za ostre predmete (torej v vsebnik iz materiala, ki ga ni mogoče prebosti, vsebnik pa je mogoče zapreti ali v podoben vsebnik).
• The recommended site is the front of the thighs. 
• Za to je priporočeno mesto na sprednjem delu stegen.
For psoriasis in patients from the age of 6 years and weighing 62.5 kg or more, the usual dose is 50 mg and should be given once weekly. 
Za psoriazo pri bolnikih od 6. leta starosti naprej in ki tehtajo 62,5 kg ali več, je običajni odmerek 50 mg, dajati pa ga je treba enkrat na teden.
Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis including ankylosing spondylitis The usual dose is 25 mg given twice a week or 50 mg once a week as an injection under the skin. 
Revmatoidni artritis, psoriatični artritis in aksialni spondilartritis, vključno z ankilozirajočim spondilitisom Običajni odmerek je 25 mg dvakrat na teden ali 50 mg enkrat na teden v obliki podkožne injekcije.
How to use Erelzi 
Kako uporabljati zdravilo Erelzi
Adjusted mean change from baseline was 3.8 for etanercept treated (n = 95) versus 0.8 for placebo treated (n = 105) patients (p < 0.001). 
Prilagojena povprečna sprememba od izhodišča je bila 3,8 pri bolnikih, zdravljenih z etanerceptom (n = 95), in 0,8 pri bolnikih, ki so prejemali placebo (n = 105) (p < 0,001).
• Twist off the cap in the direction of the arrows. 
• Pokrovček zasukajte in potegnite v smeri puščice.
By touching them, the needle guard may be activated too early. 
Z dotikom lahko namreč prezgodaj aktivirate zapiralo igle.
scaly or hard. 
čisto ali skoraj čisto
Do not use if the liquid is cloudy, discoloured, or has large lumps, flakes, or coloured particles. 
Raztopine ne uporabljajte, če je raztopina motna, obarvana ali ima velike kose, kosmiče ali barvaste delce.
What Erelzi looks like and contents of the pack 
Izgled zdravila Erelzi in vsebina pakiranja
• There may be a small amount of blood at the injection site. 
• Na mestu injiciranja se lahko pojavi nekaj krvi.
DSGAb, clear or almost clear *p ≤ 0.0001 compared with placebo a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original placebo group began receiving etanercept 25 mg BIW or 50 mg once weekly from week 13 to week 24. b. Dermatologist Static Global Assessment. 
*p ≤ 0,0001 v primerjavi s placebom a. V študijah 2 in 4 po 24 tednih niso opravili statističnih primerjav s placebom, ker je skupina, ki je prvotno dobivala placebo, začela dobivati 25 mg etanercepta dvakrat na teden ali 50 mg enkrat na teden od 13. do 24. tedna.
Administration of Erelzi should be discontinued if a patient develops a serious infection. 
Zdravljenje z zdravilom Erelzi je treba prekiniti, če pride do resne okužbe.
28b a: p < 0.001, etanercept vs. placebo b: p = 0.002, etanercept vs. placebo 
28b a: p < 0,001, etanercept proti placebu b: p = 0,002, etanercept proti placebu
If re-treatment with etanercept is indicated, the above guidance on treatment duration should be followed. 
Če je indicirano ponovno zdravljenje z etanerceptom, se ravnamo po zgornjih smernicah glede trajanja zdravljenja.
YOU MUST READ THIS BEFORE INJECTING. 
pravilno nepravilno TO MORATE PREBRATI PRED INJICIRANJEM
Whether used alone or in combination with methotrexate, Erelzi can slow down the damage to your joints caused by the rheumatoid arthritis and improve your ability to do normal daily activities. 
Zdravilo Erelzi samo ali v kombinaciji z metotreksatom lahko upočasni razvoj poškodb v sklepih zaradi revmatoidnega artritisa in izboljša sposobnost opravljanja vsakodnevnih opravil.
This includes reports of reactivation of hepatitis B in patients who were anti-HBc positive but HBsAg negative. 
vključno z etanerceptom, so poročali o reaktivaciji hepatitisa B. Poročila vključujejo tudi reaktivacijo hepatitisa B pri anti-HBc pozitivnih, vendar HBsAg negativnih bolnikih.
ASAS 20 2 weeks 
ASAS 20 2 tedna
Some have occurred within a few weeks after initiating treatment with etanercept in patients who have underlying conditions (e.g., diabetes, congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis (see section 4.4). 
Nekatere okužbe so se pojavile nekaj tednov po začetku zdravljenja bolnikov, ki so imeli poleg revmatoidnega artritisa tudi druga obolenja (npr. sladkorno bolezen, kongestivno srčno popuščanje, aktivne ali kronične okužbe v anamnezi) (glejte poglavje 4.4).
Responses were measured using the ACR Pedi 30, defined as ≥ 30% improvement in at least three of six and ≥ 30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR). 
Odzive so merili po lestvici ACR Pedi 30; izboljšanje je bilo določeno kot ≥ 30 % izboljšanje v vsaj treh od šestih glavnih kazalcev aktivnosti bolezni JRA in ≥ 30 % poslabšanje največ enega od šestih glavnih kazalcev aktivnosti bolezni JRA (število aktivno prizadetih sklepov, omejenost gibanja, zdravnikova splošna ocena, splošna ocena s strani bolnika ali staršev, ocena funkcionalnosti in hitrost sedimentacije eritrocitov).
Etanercept + Methotrexate (n = 231) 
etanercept + metotreksat (n = 231)
In each of the JIA subtypes, the majority of patients met ACR Pedi 30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender joints and physician global assessment. 
ACR Pedi 30 doseženi pri večini bolnikov, prav tako pa so pri večini bolnikov ugotovili tudi klinično izboljšanje pri sekundarnih opazovanih dogodkih, kot sta število občutljivih sklepov in zdravnikova splošna ocena.
Taking into account the PRAC Assessment Report on the PSUR(s) for etanercept (biosimilars), the scientific conclusions of CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za etanercept (podobna biološka zdravila) je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
The proportion of patients treated with etanercept who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. 
Delež bolnikov, ki so razvili protitelesa proti kardiolipinu, je bil podobno povečan pri etanerceptu v primerjavi s placebom.
Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. 
Ugotovili so, da etanercept izboljša telesno funkcijo pri bolnikih s psoriatičnim artritisom in upočasni hitrost napredovanja okvar perifernih sklepov, merjenih z rentgenskim slikanjem, pri bolnikih s poliartikularnimi simetričnimi podvrstami bolezni.
Cartons contain 1, 2 or 4 pre-filled syringes or pre-filled pens of Erelzi. 
Škatle vsebujejo 1, 2 ali 4 napolnjene injekcijske brizge ali napolnjene injekcijske peresnike z zdravilom Erelzi.
ACR 20 and 50 responses were higher in patients treated with etanercept at 3 and 6 months than in patients treated with placebo (ACR 20: etanercept 62% and 59%, placebo 23% and 11% at 3 and 6 months, respectively: ACR 50: etanercept 41% and 40%, placebo 8% and 5% at months 3 and 6, respectively; p < 0.01 etanercept vs. placebo at all timepoints for both ACR 20 and ACR 50 responses). 
(ACR 20 po 3 oz. 6 mesecih: etanercept 62 % oz. 59 %, placebo 23 % oz. 11 %; ACR 50 po 3 oz. 6 mesecih: etanercept 41 % oz. 40 %, placebo 8 % oz. 5 %; p < 0,01 za etanercept proti placebu v vseh časovnih točkah, tako za odziv ACR 20 kot za odziv ACR 50).
Disease flare was defined as a ≥ 30% worsening in three of six JRA core set criteria and ≥ 30% improvement in not more than one of the six JRA core set criteria and a minimum of two active joints. 
Ponoven izbruh bolezni je bil definiran kot ≥ 30 % poslabšanje treh od šestih osnovnih kazalcev JRA in ≥ 30 % izboljšanje največ enega od šestih glavnih kazalcev
However, your doctor may determine an alternative frequency at which to inject Erelzi. 
Zdravnik vam lahko predpiše tudi drugačno pogostnost injiciranja zdravila Erelzi.
In a 2-year active-controlled study where patients were treated with either etanercept alone, methotrexate alone or etanercept in combination with methotrexate, the rates of serious infections were similar among the treatment groups. 
V dveletni študiji, nadzorovani z učinkovino, v kateri so bili bolniki zdravljeni z etanerceptom, metotreksatom ali kombinacijo etanercepta in metotreksata, je bila stopnja pogostnosti resnih okužb v treh skupinah podobna.
Etanercept was considered to be non-genotoxic from a battery of in vitro and in vivo studies. 
Etanercept se ni izkazal za genotoksičnega v vrsti študij in vivo inin vitro.
Each pack contains 1, 2 or 4 pens, multipacks contain 12 (3 packs of 4) pens. 
Eno pakiranje vsebuje 1, 2 ali 4 peresnike, skupno pakiranje vsebuje 12 (3 pakiranja po 4) peresnikov.
*see Description of selected adverse reactions, below. 
*glejte Opis izbranih neželenih učinkov v nadaljevanju Opis izbranih neželenih učinkov
In clinical studies, concurrent administration of abatacept and etanercept resulted in increased incidences of serious adverse events. 
V kliničnih študijah je sočasna uporaba abatacepta in etanercepta zvečala pojavnost resnih neželenih učinkov.
Malignant melanoma (see section 4.4), lymphoma, leukaemia 
maligni melanom (glejte poglavje 4.4), limfom, levkemija karcinom Merklovih celic (glejte poglavje 4.4)
• If a caregiver or healthcare professional is giving you your injection, they may also inject into your outer upper arm. 
• Če vam injekcijo daje negovalec ali zdravstveni delavec, lahko zdravilo injicira tudi na zunanji strani nadlakti.
A single 50 mg/ml injection of etanercept was found to be bioequivalent to two simultaneous injections of 25 mg/ml. 
Enkratna injekcija etanercepta v odmerku 50 mg/ml je bioekvivalentna dvema sočasnima injekcijama po 25 mg/ml.
Both TNFRs exist naturally in membrane-bound and soluble forms. 
Oboji receptorjiTNF v naravi obstajajo v dveh oblikah, tj. vezani na membrano in v topni obliki.
Undesirable effects in paediatric patients with plaque psoriasis 
Neželeni učinki pri pediatričnih bolnikih s psoriazo v plakih
Infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling). 
okužbe (vključno s prehladi, sinuzitisom, bronhitisom, okužbami sečil in okužbami kože); reakcije na mestu injiciranja (vključno s krvavitvami, podplutbami, rdečino, srbenjem, bolečino in oteklino).
Additionally, some patients developed recall injection site reactions characterised by a skin reaction at the most recent site of injection, along with the simultaneous appearance of injection site reactions at previous injection sites. 
Poleg tega so nekateri bolniki razvili tako imenovano spominsko lokalno reakcijo na mestu injiciranja; ob naslednjem injiciranju se je poleg reakcije na tedanjem mestu injiciranja sočasno pojavila reakcija tudi na prejšnjih mestih injiciranja.
A risk for the development of malignancies in children and adolescents treated with TNF-antagonists cannot be excluded. 
Tveganja za razvoj malignosti pri otrocih in mladostnikih, zdravljenih z antagonisti
In this configuration the needle guard is NOT ACTIVATED and the pre-filled syringe is ready for use 
PRIPRAVLJENO NA UPORABO V tej konfiguraciji zapiralo igle NI AKTIVIRANOnapolnjena injekcijska brizga je pripravljena na uporabo
• Using a circular motion, clean the injection site with the alcohol swab. 
• Uporabite alkoholni zloženec in s krožnimi gibi očistite mesto injiciranja.
If any of the following happen, do not inject more Erelzi. 
Če se pojavi karkoli od naslednjega, zdravila Erelzi ne smete več uporabljati.
The efficacy of etanercept was assessed in a randomised, double-blind, placebo-controlled study in 211 paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA score ≥ 3, involving ≥ 10% of the BSA, and PASI ≥ 12). 
Pediatrični bolniki s psoriazo v plakih Učinkovitost etanercepta so ugotavljali v randomizirani, dvojno slepi, s placebom nadzorovani študiji pri 211 pediatričnih bolnikih, starih 4 do 17 let, z zmerno do hudo psoriazo v plakih (definirano z oceno sPGA ≥ 3, ki zajema ≥ 10 % telesne površine (BSA - Body Surface Area), in
If you forget a dose, you should inject it as soon as you remember, unless the next scheduled dose is the next day; in which case you should skip the missed dose. 
Če ste na predvideni odmerek zdravila Erelzi pozabili, ga morate injicirati takoj, ko se spomnite, razen če je naslednji odmerek predviden za naslednji dan.
Patients should be evaluated for infections before, during, and after treatment with Erelzi, taking into consideration that the mean elimination half-life of etanercept is approximately 70 hours (range 7 to 300 hours). 
Okužbe Pred zdravljenjem z zdravilom Erelzi, med njim in po njem je treba bolnike pregledati glede okužb in pri tem upoštevati, da je povprečni razpolovni čas izločanja etanercepta iz telesa približno 70 ur
70b a: 25 mg etanercept SC twice weekly b: p < 0.001, etanercept vs. placebo c: p < 0.01, etanercept vs. placebo 
70b a: 25 mg etanercepta subkutano dvakrat na teden b: p < 0,001, etanercept v primerjavi s placebom c: p < 0,01, etanercept v primerjavi s placebom
One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114 rheumatoid arthritis patients treated in clinical trials with etanercept for up to approximately 6 years, including 231 patients treated with etanercept in combination with methotrexate in a 2-year active-controlled study. 
Sto devetindvajset (129) novih malignih obolenj različnih tipov so ugotovili pri 4.114 bolnikih z revmatoidnim artritisom, zdravljenih v kliničnih preskušanjih z etanerceptom do približno 6 let,
In clinical studies conducted for more than 2 years with 351 ankylosing spondylitis patients, 6 malignancies were reported in etanercept-treated patients. 
V kliničnih študijah z etanerceptom, ki so trajale več kot 2 leti in so vključevale 351 bolnikov z ankilozirajočim spondilitisom, so poročali o 6 primerih malignega obolenja.
• Reminder to record brand name and batch number of the medication 
• opomin, da je treba zapisati trgovsko ime in številko serije zdravila;
Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-antagonists, including etanercept, has been reported. 
Reaktivacija hepatitisa B Pri bolnikih, ki so kdaj že bili okuženi z virusom hepatitisa B (HBV) in so se zdravili z zaviralci TNF,
The double-blind period was followed by an open-label period during which all patients received etanercept 50 mg weekly for up to an additional 92 weeks. 
Dvojno slepemu obdobju je sledilo odprto obdobje, med katerim so vsi bolniki prejemali etanercept v odmerku 50 mg na teden, kar je trajalo do 92 dodatnih tednov.
Compared to placebo, treatment with etanercept resulted in statistically significant improvement in the ASAS 40, ASAS 20 and ASAS 5/6. 
V primerjavi s placebom je po dajanju etanercepta prišlo do izboljšanja pri ASAS 20, ASAS 50 in
In studies when adult patients received concurrent treatment with etanercept plus anakinra, a higher rate of serious infections compared to etanercept alone was observed and 2% of patients (3/139) developed neutropenia (absolute neutrophil count ˂ 1,000/mm3). 
Sočasno zdravljenje z anakinro V študijah, v katerih so odrasli bolniki sočasno prejemali etanercept in anakinro, so opažali večjo stopnjo resnih okužb v primerjavi s samim etanerceptom in pri 2 % bolnikov (3/139) se je pojavila nevtropenija (absolutna koncentracija nevtrofilcev < 1.000/mm3).
Radiographic progression: comparison of etanercept vs. methotrexate in patients with RA of < 3 years duration 
Radiografsko napredovanje: primerjava etanercepta z metotreksatom pri bolnikih z RA, ki je trajal < 3 leta
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
A. PROIZVAJALEC (PROIZVAJALCI)BIOLOŠKE UČINKOVINE (UČINKOVIN) IN PROIZVAJALEC (PROIZVAJALCI), ODGOVOREN (ODGOVORNI) ZA
74.5% †,ϕ 
65,5 % 74,5 % †,φ
A Health Assessment Questionnaire (HAQ), which included disability, vitality, mental health, general health status, and arthritis-associated health status subdomains, was administered every 3 months during the trial. 
duševno zdravje, splošno zdravstveno stanje in poddomene zdravstvenega stanja, povezane z artritisom, so med preskušanjem uporabili vsake 3 mesece.
Significant advantages for etanercept in combination with methotrexate compared with etanercept monotherapy and methotrexate monotherapy were also observed after 24 months. 
Pomembne prednosti etanercepta v kombinaciji z metotreksatom v primerjavi z monoterapijo z etanerceptom in monoterapijo z metotreksatom so prav tako ugotovili po 24 mesecih.
Uncommon ≥ 1/1,000 to 
≥ 1/1.000 do
The active substance is etanercept. 
Učinkovina je etanercept.
Vasculitis (including antineutrophilic cytoplasmic antibody positive vasculitis) 
(vključno z vaskulitisom s pozitivnimi antinevtrofilnimi citoplazemskimi protitelesi)
Based on the review of the literature and spontaneous reporting presented in this PSUSA, covering the period from 15 July 2018 to 14 January 2019, as well as cumulative data since the European birth date, the PRAC considered that a causal relationship between inflammatory bowel disease and etanercept cannot be excluded and therefore recommends that the product information of medicinal products containing the active substance etanercept should be updated as follows: update of section 4.8 of the SmPC to add inflammatory bowel disease with a frequency uncommon. 
14. januarja 2019, ter kumulativnih podatkov od datuma pridobitve dovoljenja za promet z zdravilom v Evropi, odbor PRAC meni, da ni mogoče izključiti vzročne povezanosti med vnetno črevesno boleznijo in etanerceptom, zato priporoča posodobitev informacij o zdravilih, ki vsebujejo učinkovino etanercept, in sicer kot sledi: posodobitev poglavja 4.8 povzetka glavnih značilnosti zdravila tako, da bo vključevalo vnetno črevesno bolezen s pogostnostjo ''občasni''.
Paediatric patients weighing 62.5 kg or more can be dosed 25 mg given twice a week or 50 mg given once a week using a fixed-dose pre-filled syringe or pre-filled pen. 
Pediatrični bolniki, ki tehtajo 62,5 kg ali več, lahko odmerek 25 mg dvakrat na teden ali 50 mg enkrat na teden prejmeko kot fiksni odmerek v obliki napolnjene injekcijske brizge ali napolnjenega injekcijskega peresnika.
In a polyarticular-course juvenile idiopathic arthritis trial with etanercept, 69 patients (aged 4 to 17 years) were administered 0.4 mg etanercept/kg twice weekly for three months. 
V kliničnem preskušanju pri 69 bolnikih s poliartikularnim potekom juvenilnega idiopatskega artritisa, starih od 4 do 17 let, so injicirali 0,4 mg etanercepta/kg 2-krat tedensko v obdobju treh mesecev.
TNF and lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the 55-kilodalton (p55) 
TNF in limfotoksin sta provnetna citokina, ki se vežeta na dva različna tipa receptorjev na površini celice: 55-kilodaltonske (p55) in 75-kilodaltonske (p75) receptorje TNF.
Concurrent administration of etanercept and anakinra has been associated with an increased risk of serious infections and neutropenia compared to etanercept alone. 
Sočasno zdravljenje z anakinro Sočasna uporaba etanercepta in anakinre je bila povezana s povečanim tveganjem za pojav resnih okužb in nevtropenije v primerjavi z zdravljenjem samo z etanerceptom.
Etanercept, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. 
Dokazali so, da etanercept sam ali v kombinaciji z metotreksatom upočasni hitrost napredovanja poškodb sklepov, merjenih z rentgenskim slikanjem, in izboljša telesno funkcijo.